Eisai has announced positive topline results from the randomized, multicenter Phase 3 trial (Study 304) evaluating the company's multiple receptor tyrosine kinase inhibitor, lenvatinib (marketed as Lenvima), for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
The US Food and Drug Administration (FDA) has authorized NantKwest’s Investigational New Drug Application (IND) for its first-in-human, high-affinity natural killer (haNK) cell therapy phase I clinical study.
Otonomy has started the enrollment of the first patients in a phase 2 clinical trial assessing OTO-104 for the prevention of hearing loss in cancer patients undergoing chemotherapy with platinum-based agents.
Clinigen Group's Idis Managed Access (MA) division has partnered with TESARO to launch a Managed Access program for the investigational PARP 1/2 inhibitor, niraparib.
Hutchison China MediTech (Chi-Med) has started a Phase II study of sulfatinib in second-line biliary tract cancer (“BTC”) patients in China.
ObsEva has completed a Phase 1 single and multiple ascending dose study of OBE022, a potential first-in-class, once daily, oral and selective prostaglandin F2α, or PGF2α, receptor antagonist for the treatment of preterm labor in weeks 24 to 34 of pregnancy.
Debiopharm International has unveiled positive results from a large Phase II study of the staphylococcal-selective antibiotic Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
Seattle Genetics has enrolled the first patient in a multicenter phase 1 clinical trial of SGN-CD352A for patients with relapsed or refractory multiple myeloma (MM).
NewVac has met all primary endpoints in the Phase II Clinical Trial of Quisinostat, novel selective oral histone deacetylase (HDAC1) inhibitor, which the company licensed from Janssen Pharmaceutica.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.